Corvus Pharmaceuticals Inc (CRVS)
1.72
+0.11
(+6.83%)
USD |
NASDAQ |
May 02, 16:00
1.72
0.00 (0.00%)
After-Hours: 18:15
Corvus Pharmaceuticals Cash from Operations (Quarterly): -5.167M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -5.167M |
| September 30, 2023 | -5.434M |
| June 30, 2023 | -5.223M |
| March 31, 2023 | -8.111M |
| December 31, 2022 | -7.547M |
| September 30, 2022 | -6.929M |
| June 30, 2022 | -6.123M |
| March 31, 2022 | -6.424M |
| December 31, 2021 | -6.856M |
| September 30, 2021 | -8.425M |
| June 30, 2021 | -12.65M |
| March 31, 2021 | -8.787M |
| December 31, 2020 | -8.207M |
| September 30, 2020 | -7.732M |
| June 30, 2020 | -9.486M |
| March 31, 2020 | -9.353M |
| December 31, 2019 | -8.51M |
| September 30, 2019 | -10.61M |
| Date | Value |
|---|---|
| June 30, 2019 | -9.214M |
| March 31, 2019 | -8.99M |
| December 31, 2018 | -8.257M |
| September 30, 2018 | -10.80M |
| June 30, 2018 | -10.89M |
| March 31, 2018 | -11.04M |
| December 31, 2017 | -10.98M |
| September 30, 2017 | -10.77M |
| June 30, 2017 | -11.71M |
| March 31, 2017 | -12.75M |
| December 31, 2016 | -9.407M |
| September 30, 2016 | -6.685M |
| June 30, 2016 | -6.129M |
| March 31, 2016 | -5.636M |
| December 31, 2015 | -3.938M |
| September 30, 2015 | -3.352M |
| June 30, 2015 | -1.714M |
| March 31, 2015 | -2.324M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-12.65M
Minimum
Jun 2021
-5.167M
Maximum
Dec 2023
-7.936M
Average
-8.111M
Median
Mar 2023
Cash from Operations (Quarterly) Benchmarks
| Cyclacel Pharmaceuticals Inc | -3.91M |
| Arbutus Biopharma Corp | -17.29M |
| Oragenics Inc | -1.102M |
| Relmada Therapeutics Inc | -10.25M |
| MAIA Biotechnology Inc | -3.992M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -2.318M |
| Free Cash Flow | -23.97M |
| Free Cash Flow Per Share (Quarterly) | -0.1053 |
| Free Cash Flow Yield | -29.02% |